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Background: This study was conducted to evaluate the faecal occurrence and characterization of Clostridium
difficile in clinically healthy dogs (N = 50) and in dogs with diarrhea (N = 20) in the Stockholm-Uppsala region of
Sweden.
Findings: Clostridium difficile was isolated from 2/50 healthy dogs and from 2/20 diarrheic dogs. Isolates from
healthy dogs were negative for toxin A and B and for the tcdA and tcdB genes. Both isolates from diarrheic dogs
were positive for toxin B and for the tcdA and tcdB genes. The C. difficile isolates from healthy dogs had PCR
ribotype 009 (SE-type 6) and 010 (SE-type 3) whereas both isolates from dogs with diarrhoea had the toxigenic
ribotype 014 (SE-type 21). One of the isolates from healthy dogs was initially resistant to metronidazole.
Conclusions: This study revealed presence of toxigenic C. difficile in faecal samples of diarrheic dogs and low
number of non- toxigenic isolates in healthy dogs from Uppsala-Stockholm region in Sweden. However, more
comprehensive studies are warranted to investigate the role of C. difficile in gastrointestinal disease in dogs.
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The role of C.difficile in gastrointestinal disease in dogs
is not yet defined. Moreover, interspecies transmission
of C. difficile has also been suggested [1]. The virulence
of C. difficile is mainly related to the presence of two
exotoxins, A and B that are encoded by tcdA and tcdB
genes, respectively [2]. In addition, some strains express
a binary toxin (CDT) [3].
The aim of the present study was to evaluate the pres-
ence of C. difficile in faeces from healthy and diarrheic
dogs in the Stockholm-Uppsala region, Sweden. Toxin
production, ribotyping and antibiotic resistance pattern
of the isolates was also revealed.
Material and methods
Animals and sampling
Faecal samples from 50 healthy, randomly selected, and
20 diarrheic dogs (8 months-12 years old, median age
5 years) of varying breeds and from different households
were investigated. Eighteen of the diarrheic dogs were* Correspondence: gunilla.trowald-wigh@slu.se
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reproduction in any medium, provided the orhospitalized due to acute gastrointestinal disease involv-
ing diarrhea, whereas the remaining two dogs were
outpatients and sampled at veterinary clinics. Use of
systemic antibiotics within the last three months was
recorded in a questionnaire for the healthy dogs. Sam-
ples were collected directly upon defecation. To prevent
contamination, 10–20 g of faeces was collected with a
spoon and stored in a sterile plastic sampling tube. The
samples were kept refrigerated, and processed in the la-
boratory within 12 h after collection.
Culture conditions and bacteriological analysis
Faecal samples were plated onto C. difficile agar (CM0601
Oxoid, Basingstoke, UK) and used to inoculate C. difficile
enrichment broth. Clostridium difficile agar was sup-
plemented with moxalactam and norfloxacin (SR0173E
Oxoid) and 5% horse blood (National Veterinary Institute,
SVA, Uppsala, Sweden), and incubated anaerobically for
48 h at 37°C. Clostridium difficile broth was prepared with
the ingredients for CM0601 (agar excluded), sup-
plemented with moxalactam and norfloxacin. Briefly, 5 g
of each faecal sample was added to 10 mL broth and
mixed by vortex and incubated anaerobically at 37°C for
10 days. After incubation, the suspension was streakedral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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agar, SVA, Uppsala, Sweden) containing 5% horse blood
and incubated for 48 h.
Identification of the isolates
Clostridium difficile was tentatively identified on the
basis of Gram stain and morphology, characteristic horse
manure odour, L-proline aminopeptidase activity (Oxoid),
and then confirmed by the latex agglutination test (C. dif-
ficile test kit DR1107A, Oxoid).
Toxin detection of C. difficile
Toxin A detection was performed on fresh faeces, within
12 h after sampling, using the C. difficile toxin A test
(TD 0970A, Oxoid Ltd). Positive control (C. difficile
strain ATCC 43255) and negative control were included
in each experiment, according to the instructions of the
manufacturer. Detection of toxin B was performed by in-
oculation of isolates into C. difficile broth. The sterile
culture filtrates (48 h incubation at 37°C under anaer-
obic condition) were used in the Vero cell assay as previ-
ously described [4].
Detection of C. difficile toxin A and toxin B genes
Presence or absence of toxin A and toxin B genes were
evaluated by using PCR amplification of the A3 and B1
fragments using primer pairs and PCR protocol de-
scribed by Rupnik [5]. The analysis was performed on C.
difficile isolates.
PCR ribotyping of C. difficile
PCR ribotyping was performed according to Stubbs
et al. [6] with modifications described by Svenungsson
et al. [7]. The type was given according to the inter-
national nomenclature by using the ribotype nomencla-
ture of the Cardiff Anaerobe Reference Laboratory
(Cardiff, Wales, UK), or when reference isolates were
missing, as SE-type (Swedish type).
Antibiotic resistance pattern of the isolates
Clostridium difficile isolates were analysed for their sus-
ceptibility to five different antibiotics (Table 1). Anti-
microbial susceptibility patterns and MIC values were
determined by the Etest (AB Biodisk, Solna, Sweden)Table 1 Ribotypes, tcdA/tcdB and antibiotic susceptibility pat
dogs in Sweden
Isolate no./group Ribotype tcdA & tcdB Metronidazole
35/healthy 009 - 64,0*
38/healthy 010 - 0,064
56/diarrheic 014 + 0,125
61/diarrheic 014 + 0,032
* Result from the initial test.according to the manufacturer’s instructions. The break-
points were chosen according to The European Committee
on Antimicrobial Susceptibility Testing (EUCAST) [8].
For quality control a clinical isolate namely, (CD0903),
which is sensitive to the antibiotics in the test, was used
in parallel for each incubation. The MICs were below
current breakpoints and no drift over time has been
detected (the measured MIC ranges (mg/L) for the
control isolate are: erythromycin 0.25-1; clindamycin
0.25-1; moxifloxacin 0.5-2; metronidazole: 0.032-0.125;
vancomycin: 0.25-0.5).
Results
Clostridium difficile was isolated from 2 of the 50 healthy
dogs and from 2 of the 20 diarrheic dogs investigated.
Clostridium difficile was isolated both from primary cul-
ture and from the enrichment broth after 10 days of in-
cubation, except the isolate no. 56 that was recovered
only after enrichment.
Toxin production of C. difficile
Both C. difficile isolates (no. 56 and 61) from diarrheic
dogs were toxin B producers, and were positive for the
tcdA and tcdB genes (Table 1). However, samples from
both dogs were negative on the initial C. difficile toxin A
test performed on fresh faeces. Faeces from 4 additional
diarrheic dogs tested positive for toxin A test but bac-
teria were not isolated from these samples. The C. diffi-
cile isolates (no. 35 and 38) from healthy dogs were
negative for the tcdA and tcdB genes (Table 1). Culture
filtrates from these samples were negative for toxin B,
and all faeces from the animals from which the isolates
were obtained were negative for toxin A.
PCR ribotyping
The isolates from healthy dogs were classified as PCR
ribotype 009/SE-type 6 (isolate no. 35) and 010/SE-type
3 (isolate no. 38), whereas both isolates from diarrheic
dogs had PCR ribotype 014/ SE-type 21 (Table 1).
Antibiotic treatment of the dogs and resistance pattern of
the isolates
Two of the healthy dogs investigated were treated with
metronidazole and amoxicillin with clavulanic acidterns with MIC values (mg/L) of C. difficile isolated from
Vancomycin Clindamycin Erytromycin Moxifloxacin
0,5 0,5 1,0 1,0
0,5 2,0 2,0 1,0
0,5 2,0 2,0 2,0
0,5 4,0 1,0 2,0
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isolate no. 35 was isolated from the dog that was treated
with metronidazole, and this isolate was initially resist-
ant to high levels of metronidazole: 64 mg/L (Table 1).
However, high level metronidazole resistance was not
maintained; subsequent subcultures following recovery
from frozen storage were resistant to between 2 and
8 mg/L of antibiotic. Isolate no. 38 was isolated from a
dog without history of antibiotic treatment, and this
strain did not show elevated resistance to the antibiotics
tested. Seven of the 20 diarrheic dogs were treated with an-
tibiotics at the animal hospital or within 3 months before
sampling. Antibiotic treatments in these dogs included
amoxicillin (N = 1), ampicillin (N = 2) and metronidazole
(N = 2), metronidazole and amoxillin with clavulanic acid
(N = 1), amoxicillin, ampicillin and metronidazole (N = 1).
Isolate no. 56 was from a dog treated with metronidazole
during hospital stay. Isolate no. 61 was isolated from a dog
treated (at the hospital), during recurrent diarrheic epi-
sodes, with ampicillin, metronidazole and amoxicillin re-
spectively. One of the dogs that tested positive for the
presence of toxin A, but was culture negative, had been
treated with metronidazole and amoxicillin with clavulanic
acid. Resistance patterns of the isolates are shown in
Table 1.
Discussion
Clostridium difficile was isolated in 2/50 of the healthy
dogs and in 2/20 of the diarrheic dogs. Additionally,
toxin A was detected in the faeces of diarrheic dogs and
toxigenic bacteria were only isolated from diarrheic
dogs, whereas toxin A was not detected in the faeces of
any healthy dogs. Both isolates from healthy dogs were
PCR negative for the tcdA and tcdB toxin genes. In four
diarrheic dogs toxin A was detected in faeces samples
but C. difficile was not isolated. On the other hand the
C. difficile isolated from faeces of two diarrheic dogs
were cdtA/cdtB positive but negative in the initial toxin
A test performed on fresh faeces. Possible explanations
for this phenomenon could be that C. difficile is a strict
anaerobe bacterium and the recovery and cultivation of
the microorganism can be difficult. Also, the bacteria
can be present in the faeces although in very small num-
ber and therefore, in some cases, undetectable. Further-
more, very little is known about the actual excretion of
toxins in the different phases of C. difficile colonisation/
infection. This factor could also explain the negative re-
sults in the initial toxin A test.
There is wide variation in the reported C. difficile car-
riage rate among household pets. Different studies de-
scribes occurrence of C. difficile in faecal samples of
dogs ranging from 0% to 21% [9-12]. Both toxigenic and
non-toxigenic isolates are reported. Several factors may
contribute to these discrepancies, including differentmethods of isolation and detection, prior use of antibi-
otics, geographical location, age or breed of animals.
Both isolates from diarrheic dogs had the toxigenic
ribotype 014 associated with clinical disease in humans
[13], while isolates from healthy dogs revealed nontoxigenic
PCR ribotypes 009 and 010. Ribotype 010 is occasionally
isolated from human faeces in Sweden while type 009 is
uncommon [14], whereas ribotype 014 is commonly
detected in clinical specimens from human patients in
Sweden [15].
Evidence of antibiotic resistance in C. difficile isolates
from humans is growing, but reports of antibiotic resistant
strains from dogs are rare [13,16]. Marks and Kather [16]
reported that all C. difficile isolated from diarrheic and
nondiarrheic dogs were susceptible to metronidazole and
vancomycin, leading to the recommendation that these
drugs are appropriate for use in treating infection. How-
ever, in our study, one of the C. difficile isolates from a
healthy dog (no. 35), treated with metronidazole, was ini-
tially resistant to metronidazole (MIC = 64 mg/L). The
dog from which this isolate originated was treated for gin-
givitis with metronidazole one month before sampling.
The high level of metronidazole resistance in this purified
strain was unstable and decreased to 2 mg/L, which may
be due to the absence of continual antibiotic selection.
This phenomenon has been reported by Pelaez et al. [17]
and Huang et al. [18] on human isolates and is not fully
understood. The lack of continuous selection in vitro
might lead to loss of resistance. Genetic determinants of
resistance in C. difficile are not known but may be on an
unstable plasmid that is lost without continuous selection.
Metronidazole unresponsive C. difficile infection has been
discussed as an emerging problem in humans [19] but re-
sistance against metronidazole has not to our knowledge
previously been reported in C. difficile isolates from dogs.
In conclusion, our work contributes to the growing evi-
dence on the occurrence of toxigenic and nontoxigenic C.
difficile in dogs. This study revealed presence of toxigenic
C. difficile in faecal samples of diarrheic dogs and low
number of non- toxigenic isolates in healthy dogs. How-
ever, more comprehensive studies are warranted to inves-
tigate the role of C. difficile in gastrointestinal disease in
dogs. Also, the finding of toxigenic ribotype 014 in diar-
rheic dogs might imply a potential zoonotic risk. In
addition, one C. difficile isolate was initially resistant to
metronidazole, and acquisition of resistance to this com-
mon drug of choice in dogs should be considered in veter-
inary clinical practice.
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